Sutro Biopharma, Inc. (STRO)

Price$26.09

Value ScoreC

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)175.97%

Price vs S&P 500 (4W)-35.15%

VGM Score59.94

Market Capitalization$432.32M

All Metrics

Book Value / Share (Quarterly)$0.53

P/TBV (Annual)0.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.78%

Cash Flow / Share (Quarterly)$-9.18

Price vs S&P 500 (YTD)117.34%

Net Profit Margin (TTM)-154.21%

EPS (TTM)$-16.35

10-Day Avg Trading Volume0.36M

EPS Excl Extra (TTM)$-16.35

Revenue Growth (5Y)19.13%

EPS (Annual)$-22.49

ROI (Annual)-509.99%

Net Profit Margin (5Y Avg)-193.80%

Cash / Share (Quarterly)$12.23

Revenue Growth QoQ (YoY)-16.53%

ROA (Last FY)-109.93%

Revenue Growth TTM (YoY)49.94%

EBITD / Share (TTM)$-11.64

ROE (5Y Avg)-137.55%

Operating Margin (TTM)-119.98%

Cash Flow / Share (Annual)$-20.84

P/B Ratio9.83x

P/B Ratio (Quarterly)3.45x

Net Income / Employee (Annual)$-1,394,800

EV / Revenue (TTM)3.60x

Net Interest Coverage (TTM)-14.06x

ROA (TTM)-69.20%

EPS Incl Extra (Annual)$-22.49

Current Ratio (Annual)2.01x

Quick Ratio (Quarterly)3.04x

3-Month Avg Trading Volume0.23M

52-Week Price Return216.63%

Revenue / Employee (TTM)$727,100

Tangible BV / Share (Quarterly)$1.84

P/S Ratio (Annual)4.22x

Asset Turnover (Annual)0.59x

52-Week High$43.85

Operating Margin (5Y Avg)-189.28%

EPS Excl Extra (Annual)$-22.49

CapEx CAGR (5Y)-24.97%

26-Week Price Return183.90%

Quick Ratio (Annual)1.94x

13-Week Price Return15.96%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.12x

Enterprise Value$358.64M

Revenue / Share Growth (5Y)55.85%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)5.00%

Revenue / Employee (Annual)$748,100

Pretax Margin (Annual)-186.55%

Cash / Share (Annual)$16.48

3-Month Return Std Dev90.17%

Net Income / Employee (TTM)$-1,121,200

ROE (Last FY)-509.99%

Net Interest Coverage (Annual)-5.34x

EPS Basic Excl Extra (Annual)$-22.49

P/FCF (TTM)20.00x

Receivables Turnover (TTM)7.65x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-16.35

Receivables Turnover (Annual)16.28x

ROI (TTM)-223.84%

P/S Ratio (TTM)4.34x

Pretax Margin (5Y Avg)-189.95%

Revenue / Share (Annual)$12.06

Tangible BV / Share (Annual)$3.77

Price vs S&P 500 (52W)192.26%

Year-to-Date Return125.50%

5-Day Price Return-7.65%

EPS Normalized (Annual)$-22.49

ROA (5Y Avg)-50.31%

Net Profit Margin (Annual)-186.45%

Month-to-Date Return-10.74%

Cash Flow / Share (TTM)$-2.80

EBITD / Share (Annual)$-17.77

Operating Margin (Annual)-154.53%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-135.52%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-16.35

P/TBV (Quarterly)1.33x

P/B Ratio (Annual)3.40x

Pretax Margin (TTM)-154.32%

Book Value / Share (Annual)$5.40

Price vs S&P 500 (13W)7.70%

Beta1.57x

P/FCF (Annual)38.88x

Revenue / Share (TTM)$7.61

ROE (TTM)-223.84%

52-Week Low$6.74

vGradeC

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-2.94est. -3.85

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.81

3.94

4.00

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
STROSutro Biopharma, Inc.	C	C	B	$26.09
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Sutro Biopharma is a clinical-stage biopharmaceutical company developing protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF cell-free protein synthesis platform. Lead programs include STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers, with additional candidates in development.